Haixin Huang

1.5k total citations · 1 hit paper
23 papers, 882 citations indexed

About

Haixin Huang is a scholar working on Oncology, Otorhinolaryngology and Molecular Biology. According to data from OpenAlex, Haixin Huang has authored 23 papers receiving a total of 882 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Otorhinolaryngology and 9 papers in Molecular Biology. Recurrent topics in Haixin Huang's work include Head and Neck Cancer Studies (10 papers), Lung Cancer Research Studies (4 papers) and RNA modifications and cancer (3 papers). Haixin Huang is often cited by papers focused on Head and Neck Cancer Studies (10 papers), Lung Cancer Research Studies (4 papers) and RNA modifications and cancer (3 papers). Haixin Huang collaborates with scholars based in China and United States. Haixin Huang's co-authors include Shengming Dai, Guisheng Li, Zhen Wu, Xiangyang Zhou, Xiaomou Wei, Dong Wei, Chen Shao-jun, Hua Li, Ying Lu and Baoyu He and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Haixin Huang

20 papers receiving 870 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer

2008 670 citations Shengming Dai, Dong Wei et al. Molecular Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haixin Huang China	8	722	476	174	122	82	23	882
Lizandra Jimenez United States	7	569 0.8×	375 0.8×	107 0.6×	104 0.9×	79 1.0×	13	708
Meiyu Fang China	14	652 0.9×	374 0.8×	152 0.9×	298 2.4×	101 1.2×	65	985
Shashi K. Gopal Australia	10	1.2k 1.6×	728 1.5×	240 1.4×	142 1.2×	113 1.4×	10	1.3k
Theofanis Floros Greece	6	327 0.5×	185 0.4×	228 1.3×	258 2.1×	46 0.6×	11	618
Malgorzata Harasymczuk United States	13	325 0.5×	176 0.4×	740 4.3×	462 3.8×	40 0.5×	16	1.1k
Haikuo Tang China	13	424 0.6×	289 0.6×	41 0.2×	134 1.1×	44 0.5×	16	622
Nicholas D. Stafford United Kingdom	14	174 0.2×	137 0.3×	148 0.9×	327 2.7×	108 1.3×	31	617
Zachary Brownlee United States	10	275 0.4×	356 0.7×	124 0.7×	512 4.2×	114 1.4×	13	848
Anupama Pal United States	14	637 0.9×	140 0.3×	121 0.7×	397 3.3×	23 0.3×	18	859
Ann Georgelas United States	11	194 0.3×	144 0.3×	118 0.7×	144 1.2×	32 0.4×	12	565

Countries citing papers authored by Haixin Huang

Since Specialization

Citations

This map shows the geographic impact of Haixin Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haixin Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haixin Huang more than expected).

Fields of papers citing papers by Haixin Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haixin Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haixin Huang. The network helps show where Haixin Huang may publish in the future.

Co-authorship network of co-authors of Haixin Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Haixin Huang. A scholar is included among the top collaborators of Haixin Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haixin Huang. Haixin Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nawaz, Asad, Jinpeng Zhang, Haixin Huang, et al.. (2025). Machine learning based insights into cardiomyopathy and heart failure research: a bibliometric analysis from 2005 to 2024. Frontiers in Medicine. 12. 1602077–1602077.

Lu, Ying, et al.. (2024). Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma. Cellular and Molecular Neurobiology. 45(1). 6–6. 1 indexed citations

Lu, Ying, Haixin Huang, Hui Yang, et al.. (2022). Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study. Journal of Cancer Research and Clinical Oncology. 149(8). 4327–4338. 5 indexed citations

Lu, Ying, Jiang Zhou, Huan Lin, et al.. (2022). Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma. Future Oncology. 18(22). 2441–2451. 2 indexed citations

Chen, Shanshan, Yiqun Han, Quchang Ouyang, et al.. (2021). Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy. BMC Cancer. 21(1). 341–341. 4 indexed citations

Li, Hua, Shaojun Chen, Lin Zhan, et al.. (2021). Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin. Cancer Biotherapy and Radiopharmaceuticals. 37(1). 2–10. 3 indexed citations

Lu, Ying, et al.. (2019). Induction Therapy of Nituzumab Combined PF Regimen to Improve the Treatment Response and Tolerance of Locally Advanced Nasopharyngeal Carcinoma Undergoing the Concurrent Chemoradiotherapy: A Multi-Center Controlled Randomized Clinical Study. International Journal of Radiation Oncology*Biology*Physics. 105(1). E393–E394. 2 indexed citations

Lu, Ying, Dagui Chen, Jinhui Liang, et al.. (2019). Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study. BMC Cancer. 19(1). 1262–1262. 24 indexed citations

Chen, Haihui, Haixin Huang, Megan E. Daly, et al.. (2019). Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer. Practical Radiation Oncology. 10(5). e372–e377. 11 indexed citations

10.

Xu, Rui‐Hua, Fenggong Wang, Fanchao Feng, et al.. (2018). Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study. Annals of Oncology. 29. viii409–viii409. 5 indexed citations

11.

Kang, Min, Haixin Huang, Bin Yu, et al.. (2017). A phase II randomized, multicentric clinical trail comparing recombinant human endostatin plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locally advanced low-risk nasopharyngeal carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 6063–6063. 1 indexed citations

12.

Chen, Haihui, et al.. (2017). Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma. Medicine. 96(44). e8202–e8202. 20 indexed citations

13.

He, Baoyu, Jianchao Zeng, Chao Wei, et al.. (2017). Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. Oncotarget. 8(25). 41166–41177. 66 indexed citations

14.

Zhang, Jianyuan, Shaojun Chen, Guisheng Li, et al.. (2017). Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Cancer Chemotherapy and Pharmacology. 79(6). 1087–1097. 8 indexed citations

15.

Lu, Ying, Haixin Huang, Hui Yang, & Dagui Chen. (2017). Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer. Medicine. 96(41). e8252–e8252. 7 indexed citations

16.

Lu, Ying, Haixin Huang, Min Kang, et al.. (2017). Combined Ki67 and ERCC1 for prognosis in non-keratinizing nasopharyngeal carcinoma underwent chemoradiotherapy. Oncotarget. 8(51). 88552–88562. 6 indexed citations

17.

Lu, Ying, Haixin Huang, Hui Yang, et al.. (2017). Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma. Cell Cycle. 16(14). 1376–1383. 10 indexed citations

18.

Li, Qin, Haixin Huang, Haihui Chen, & Guisheng Li. (2012). Relationship between expression of ERCC1 and concurrent chemo-radiotherapy in patients with nasopharyngeal cancer. 24(11). 738–741. 1 indexed citations

19.

Li, Guisheng, et al.. (2011). A randomized clinical study of intensity-modulated radiotherapy vs conventional radiotherapy combined with chemotherapy in treating local/regional advanced nasopharyngeal carcinoma. Tumori. 31(4). 343–347. 1 indexed citations

20.

Dai, Shengming, Dong Wei, Zhen Wu, et al.. (2008). Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer. Molecular Therapy. 16(4). 782–790. 670 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact